US 12,358,950 B2
IL-17A binding peptides and medical uses thereof
Marcello Allegretti, L'Aquila (IT); Andrea Aramini, L'Aquila (IT); Andrea Beccari, L'Aquila (IT); Marica Gemei, Naples (IT); and Flavio Mantelli, L'Aquila (IT)
Assigned to Dompe' Farmaceutici S.P.A., Milan (IT)
Filed by Dompe' Farmaceutici S.P.A., Milan (IT)
Filed on Dec. 17, 2021, as Appl. No. 17/555,154.
Application 17/555,154 is a division of application No. 17/158,728, filed on Jan. 26, 2021, granted, now 11,236,129.
Application 17/158,728 is a continuation of application No. PCT/EP2019/070265, filed on Jul. 26, 2019.
Claims priority of application No. 18186029 (EP), filed on Jul. 27, 2018.
Prior Publication US 2022/0112244 A1, Apr. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 7/08 (2006.01); A61K 38/00 (2006.01)
CPC C07K 7/08 (2013.01) [A61K 38/00 (2013.01)] 10 Claims
 
1. A peptide that specifically inhibits IL-17A binding to ILRA, comprising the amino acid sequence of Formula (I), wherein Formula (I) comprises an amino acid sequence selected from SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 169, SEQ ID NO: 181, SEQ ID NO: 192, SEQ ID NO: 194, SEQ ID NO: 195, SEQ ID NO: 197, SEQ ID NO: 214, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 223, SEQ ID NO: 262, or SEQ ID NO: 263.